Recent advances in genomics and therapeutics in mantle cell lymphoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in genomics and therapeutics in mantle cell lymphoma
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume -, Issue -, Pages 102651
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.ctrv.2023.102651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
- (2023) Javier Muñoz et al. ONCOLOGIST
- Treatment approaches for patients with TP53-mutated mantle cell lymphoma
- (2023) Thomas E Lew et al. Lancet Haematology
- A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma
- (2023) Geoffrey Shouse et al. Blood Advances
- Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma
- (2023) Francesco Gaudio et al. Clinical Lymphoma Myeloma & Leukemia
- NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications
- (2023) Leigh Deshotels et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
- (2023) Yucai Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma
- (2023) Michael L. Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data
- (2023) Alessia Zinzi et al. PHARMACOLOGICAL RESEARCH
- Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy
- (2023) Demis N. Lipe et al. Frontiers in Oncology
- Long term follow-up of Rituximab plus Bendamustine and Cytarabine (R-BAC) in elderly patients with newly diagnosed MCL
- (2023) Maria Chiara Tisi et al. Blood Advances
- Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
- (2023) Tycel J. Phillips et al. Blood Advances
- Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy
- (2023) J. Karolová et al. AMERICAN JOURNAL OF HEMATOLOGY
- CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
- (2023) Salomé Decombis et al. BLOOD
- Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
- (2023) Steven Le Gouill et al. HAEMATOLOGICA
- Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
- (2023) Letong Cai et al. Journal of Hematology & Oncology
- Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
- (2023) Neeraj Jain et al. Journal of Hematology & Oncology
- Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease
- (2023) Thomas E. Lew et al. LEUKEMIA & LYMPHOMA
- The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
- (2023) Tingxun Lu et al. Experimental Hematology & Oncology
- Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study
- (2022) Pallawi Torka et al. CANCER
- Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
- (2022) Michael L Wang et al. LANCET ONCOLOGY
- Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
- (2022) Preetesh Jain et al. AMERICAN JOURNAL OF HEMATOLOGY
- Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
- (2022) Yuqin Song et al. BLOOD
- Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
- (2022) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
- (2022) Madelyn Burkart et al. Journal of Personalized Medicine
- Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
- (2022) Fereshteh Ameli et al. BMC CANCER
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
- (2022) Michael Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
- (2022) Peter Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Mantle-Cell Lymphoma
- (2022) James O. Armitage et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
- (2022) Shazia Nakhoda et al. BRITISH JOURNAL OF HAEMATOLOGY
- Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
- (2022) Alexander D. Heini et al. Cells
- A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
- (2022) Amineh Ghaderi et al. Pharmaceutics
- Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
- (2022) Martin Dreyling et al. BLOOD
- Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
- (2022) Hun Ju Lee et al. BLOOD
- Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
- (2022) Adrian Minson et al. BLOOD
- Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
- (2022) Michael Winkelmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma
- (2022) Yang Liu et al. HAEMATOLOGICA
- Bendamustine and rituximab is well‐tolerated and efficient in the treatment of indolent non‐Hodgkin ' s lymphoma and mantle cell lymphoma in elderly: A single center observational study
- (2022) Rouslan Kotchetkov et al. INTERNATIONAL JOURNAL OF CANCER
- High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
- (2022) Olivier Hermine et al. JOURNAL OF CLINICAL ONCOLOGY
- Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
- (2022) Mazyar Shadman et al. Lancet Haematology
- Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
- (2022) Narendranath Epperla et al. Blood Advances
- Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
- (2021) Alessia Castellino et al. Blood Cancer Journal
- Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients
- (2021) Rory McCulloch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
- (2021) Anthony R Mato et al. LANCET
- T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease
- (2021) Thomas E. Lew et al. BONE MARROW TRANSPLANTATION
- SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma
- (2021) Shashidhar S. Jatiani et al. CLINICAL CANCER RESEARCH
- ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.
- (2021) Mitchell Reed Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.
- (2021) Tycel Jovelle Phillips et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
- (2021) Michael Roost Clausen et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
- (2021) Martin Hutchings et al. LANCET
- EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
- (2021) Diana Martinez-Baquero et al. MODERN PATHOLOGY
- Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management
- (2021) Krista M. Isaac et al. Current Oncology Reports
- Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial
- (2021) Anna-Katharina Zoellner et al. Lancet Haematology
- Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
- (2021) Constantine S. Tam et al. Blood Advances
- Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy
- (2021) David A Bond et al. Blood Advances
- Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
- (2021) Tycel Phillips et al. BLOOD
- Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies
- (2021) Mazyar Shadman et al. BLOOD
- Therapeutic options for relapsed/refractory mantle cell lymphoma
- (2021) Toby A. Eyre et al. BLOOD
- Survival in mantle cell lymphoma after frontline treatment with Rbendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
- (2021) Alexandra Albertsson-Lindblad et al. HAEMATOLOGICA
- Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
- (2021) Preetesh Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
- (2021) Lihua E. Budde et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
- (2021) Michael Wang et al. Journal of Hematology & Oncology
- Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
- (2021) Jacob D Soumerai et al. Lancet Haematology
- Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
- (2021) Giulia Bega et al. Cancers
- Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
- (2020) Sasanka M. Handunnetti et al. BLOOD
- Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
- (2020) Rory McCulloch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
- (2020) Chunlong Zhao et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( MCL ) ‐ outcomes and mutation profile from venetoclax resistant MCL patients
- (2020) Shuangtao Zhao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
- (2020) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Novel agents for mantle cell lymphoma: molecular rational and clinical data
- (2020) Clémentine Sarkozy et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
- (2020) Franck Morschhauser et al. HAEMATOLOGICA
- Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
- (2020) Margaux Lejeune et al. Frontiers in Immunology
- Molecular Pathogenesis of Mantle Cell Lymphoma
- (2020) Alba Navarro et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
- (2020) Carlo Visco et al. LEUKEMIA
- Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
- (2020) Diana Malarikova et al. Cancers
- Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis
- (2020) Holly A. Hill et al. Blood Advances
- Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma
- (2020) Diego Villa et al. Blood Advances
- High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
- (2020) Preetesh Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Mantle cell lymphoma with gastrointestinal involvement and the role of endoscopic examinations
- (2020) Han Hee Lee et al. PLoS One
- Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- (2020) Mehdi Hamadani et al. BLOOD
- Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
- (2020) Steven Le Gouill et al. BLOOD
- Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review
- (2020) Neerav Monga et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
- (2019) James N. Gerson et al. JOURNAL OF CLINICAL ONCOLOGY
- Modulation of immune checkpoint molecule expression in mantle cell lymphoma
- (2019) Bonnie K. Harrington et al. LEUKEMIA & LYMPHOMA
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
- (2019) Peter Martin et al. BLOOD
- Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
- (2019) Liang Zhang et al. Science Translational Medicine
- KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
- (2019) Simone Ferrero et al. HAEMATOLOGICA
- Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
- (2019) Michael Wang et al. LEUKEMIA
- Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma
- (2019) Shelby Sloan et al. BLOOD
- Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience
- (2019) Nikesh Shah et al. BLOOD
- Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment
- (2019) Akriti Gupta Jain et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial
- (2019) Hanneke C. Kluin-Nelemans et al. JOURNAL OF CLINICAL ONCOLOGY
- SOX11 augments BCR signaling to drive MCL-like tumor development
- (2018) Pei-Yu Kuo et al. BLOOD
- Composite morphologically and immunohistochemically distinct classical and pleomorphic mantle cell lymphomas
- (2018) Huan-You Wang et al. BLOOD
- A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma
- (2018) Guillem Clot et al. BLOOD
- Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
- (2018) Oshrat Hershkovitz-Rokah et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma
- (2018) Hun J. Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy
- (2018) I. Brian Greenwell et al. CANCER
- Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
- (2018) Jorge E. Romaguera et al. CANCER
- Genomic landscape and prognostic analysis of mantle cell lymphoma
- (2018) Ping Yang et al. CANCER GENE THERAPY
- Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
- (2018) Yazeed Sawalha et al. Clinical Lymphoma Myeloma & Leukemia
- A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
- (2018) Victor Yazbeck et al. Clinical Lymphoma Myeloma & Leukemia
- Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
- (2018) Christian Winther Eskelund et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma
- (2018) Oscar Calzada et al. LEUKEMIA & LYMPHOMA
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
- (2018) John C. Byrd et al. Oncotarget
- Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
- (2018) Christian Winther Eskelund et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
- (2018) Mats Jerkeman et al. Lancet Haematology
- Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
- (2018) Jia Ruan et al. BLOOD
- Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
- (2018) Toby A. Eyre et al. HAEMATOLOGICA
- Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis
- (2018) Simon Rule et al. HAEMATOLOGICA
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
- (2018) Tadeusz Robak et al. LANCET ONCOLOGY
- A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib
- (2018) Nagendra K. Chaturvedi et al. LEUKEMIA & LYMPHOMA
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
- (2018) Rishu Agarwal et al. NATURE MEDICINE
- Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma
- (2018) Hui Guo et al. ONCOGENE
- Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
- (2017) Francesco Zaja et al. HAEMATOLOGICA
- Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study
- (2017) Narendranath Epperla et al. HEMATOLOGICAL ONCOLOGY
- Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
- (2017) Steven Le Gouill et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
- (2017) Francesco Zaja et al. HAEMATOLOGICA
- Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
- (2017) Carlo Visco et al. Lancet Haematology
- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- (2016) A. Albertsson-Lindblad et al. BLOOD
- RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
- (2016) Robert W. Chen et al. BRITISH JOURNAL OF HAEMATOLOGY
- 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
- (2016) Christian W. Eskelund et al. BRITISH JOURNAL OF HAEMATOLOGY
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma
- (2016) Jonathon B. Cohen et al. CANCER
- Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
- (2016) Qingshan Yang et al. CLINICAL CANCER RESEARCH
- Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
- (2016) Ashwini Balakrishnan et al. CLINICAL CANCER RESEARCH
- Mantle Cell Lymphoma
- (2016) Chan Yoon Cheah et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
- (2016) Olivier Hermine et al. LANCET
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
- (2016) Atish Mohanty et al. Oncotarget
- Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
- (2015) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
- (2015) Z. A. Hing et al. BLOOD
- miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator
- (2015) S. Husby et al. BLOOD
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
- (2015) M.-H. Delfau-Larue et al. BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
- (2015) A. M. Evens et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
- (2015) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- MYC overexpression correlates withMYCamplification or translocation, and is associated with poor prognosis in mantle cell lymphoma
- (2015) Ji-Young Choe et al. HISTOPATHOLOGY
- Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study
- (2015) Susanne Schreiber et al. LEUKEMIA & LYMPHOMA
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone Acetylation Enzymes Coordinate Metabolism and Gene Expression
- (2015) Yuan Shen et al. TRENDS IN PLANT SCIENCE
- Autologous hematopoietic stem cell transplantation in elderly patients (≥70years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study
- (2015) E. Hermet et al. Journal of Geriatric Oncology
- The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells
- (2014) J. Zhang et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
- (2014) Michael Wang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
- (2013) S. H. Bernstein et al. ANNALS OF ONCOLOGY
- Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
- (2013) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- Absolute monocyte count at diagnosis and survival in mantle cell lymphoma
- (2013) Luis F. Porrata et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic impact of monocyte count at presentation in mantle cell lymphoma
- (2013) Kathrin Aprile von Hohenstaufen et al. BRITISH JOURNAL OF HAEMATOLOGY
- microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics
- (2013) A. Navarro et al. CLINICAL CANCER RESEARCH
- Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index
- (2013) Clémentine Sarkozy et al. GENES CHROMOSOMES & CANCER
- First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group
- (2013) R. Arranz et al. HAEMATOLOGICA
- Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells
- (2013) L. Wang et al. HAEMATOLOGICA
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma
- (2013) Rashmi S. Goswami et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality
- (2013) Timothy S. Fenske et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Risk factors of central nervous system relapse in mantle cell lymphoma
- (2013) Annarita Conconi et al. LEUKEMIA & LYMPHOMA
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autologous transplantation and management of younger patients with mantle cell lymphoma
- (2012) Christian H. Geisler BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
- (2012) A. Navarro et al. CANCER RESEARCH
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
- (2011) J. W. Friedberg et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
- (2011) Francesco Merli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
- (2011) A M Halldórsdóttir et al. LEUKEMIA
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
- (2010) M. Sant et al. BLOOD
- Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
- (2010) Jorge E. Romaguera et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
- (2009) C. S. Tam et al. BLOOD
- Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
- (2009) Antonina V. Kurtova et al. BLOOD
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
- (2009) Lloyd E. Damon et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
- (2009) Peter Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling
- (2008) S. Bea et al. BLOOD
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started